Empowering healthcare with innovative solutions.
Orbit Pharma Laboratories
Orbit Pharma Laboratories began its journey in 1989, when its founder, Mr. N. P. Kikani, along with his partners, acquired land in Chhatral after beginning their work in API manufacturing in Naroda. In 1992, Orbit Pharma Laboratories received its first FDA licence, marking an important milestone in the company’s journey in pharmaceutical manufacturing. Over the years, the company built its expertise through quality manufacturing, job work, and pharmaceutical projects for established organisations.
A significant turning point came in 2010, when Mr. Kunal Kikani joined the business and took an active role in driving its growth. Starting with a capacity of approximately 20–25 KL and an annual turnover of around ₹1.5 crore, Orbit gradually expanded its manufacturing capabilities, infrastructure, product portfolio, and market presence. From introducing its first product, Diclofenac, in 2010 to expanding into a wider range of APIs and intermediates, Orbit has continuously strengthened its capabilities. The company has also built long-term relationships with leading pharmaceutical organisations and developed a strong presence in regulated markets.
In 2020, the partnership firm was converted into Orbit Pharma Laboratories LLP, with Mr. Kunal Kikani, Mr. N. P. Kikani, and Mrs. S. M. Kikani as partners. In 2024, the company transitioned into Orbit Pharma Laboratories Limited. Today, Orbit has a team of approximately 150 people, approvals and vendor qualifications from more than 100–150 companies, and a growing portfolio of pharmaceutical products and intermediates.
With continuous investments in infrastructure, technology, quality systems, and new molecules, Orbit Pharma is building the foundation for its next phase of growth.
Our Mission
Our mission is to build a pharmaceutical organisation driven by quality, reliability, innovation, and responsible growth.
We are committed to delivering high-quality APIs and intermediates while continuously strengthening our manufacturing capabilities, infrastructure, and quality systems.
As the industry evolves, we aim to embrace new molecules, advanced technologies, and specialised manufacturing capabilities, while building lasting relationships with our customers and partners.
Our focus is on creating long-term value through efficient processes, high-value products, continuous improvement, and uncompromising quality.
Our Mission
We prioritize quality in every aspect of our operations, invest in innovation to meet market demands, and build strong customer relationships by providing reliable, effective products. We are committed to sustainability, minimizing our environmental impact, and fostering a culture of teamwork and employee empowerment to drive collective success.
Our Vision
Our vision is to take Orbit Pharma Laboratories to the next level by expanding into newer, higher-value molecules and regulated markets.
We aim to strengthen our existing market presence while exploring opportunities across therapeutic segments such as anti-diabetic, anti-fungal, cardiac, and oncology products.
Over the next three years, we aspire to grow Orbit Pharma into a ₹500+ crore organisation, supported by expanded manufacturing capabilities, advanced technology, new facilities, and stronger quality and regulatory systems.
Our focus is on building higher-value capabilities, sustainable growth, and a stronger future for Orbit Pharma.
Our Vision
To be a global leader in the pharmaceutical industry by delivering innovative, high-quality API solutions that enhance human and animal health. We are committed to setting industry standards through sustainability, excellence, and ethical practices. Our goal is to improve lives while minimizing environmental impact. We strive to make a meaningful difference in healthcare worldwide.
Core Values
Quality
Integrity
Innovation
Customer
Centric
Excelence
Mr. Kunal Kikani
MD
Mr. Kunal Kikani joined Orbit Pharma Laboratories in 2010 after completing his Bachelor’s degree in Chemical Engineering. At the time, the company had a team of just 12 people, a manufacturing capacity of approximately 20–25 KL, and a turnover of around ₹1.5 crore.
Since then, Kunal has played a pivotal role in transforming and expanding the organisation. He introduced Diclofenac as one of his early initiatives and, from 2013 onwards, focused on systematically upgrading the company’s equipment, infrastructure, and manufacturing capabilities.
Under his leadership, Orbit has expanded its product portfolio, strengthened industry partnerships, increased its manufacturing capacity, and built a stronger market presence.
From a team of 12 in 2010, Orbit has grown to approximately 150 employees, with a turnover of around ₹58 crore last year and a target of ₹100 crore in the coming year.
Driven by a focus on quality, innovation, continuous improvement, and long-term growth, Kunal continues to lead Orbit Pharma towards its vision of becoming a ₹500+ crore organisation, with a growing focus on newer molecules, regulated markets, and higher-value pharmaceutical products.
Mr. Kunal Kurkani
MD
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, It was popularised in the 1960s with the release of Letraset sheets containing. Aldus PageMaker including versions of Lorem Ipsum.
